Naurex raises $18M for Ph2 depression program

Evanston, IL-based Naurex is banking an $18 million Series A for its work on a new treatment for depression. And it's gained some significant support from a group of venture backers which includes a trio of pharma investment arms. Adams Street Partners and Latterell Venture Partners led the round with  Druid BioVentures, Genesys Capital, PathoCapital, Lundbeck, Takeda Ventures and Shire taking part. Much of the money will be used for a Phase II trial of GLYX-13, a glycine-site functional partial agonist selective modulator of the NMDA receptor. Naurex release

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.